Dutch scientists have developed a laboratory tool capable of reading DNA in long, continuous strands rather than fragmented sections. This breakthrough offers a new path for diagnosing rare hereditary conditions that have long remained medical mysteries, ending years of uncertainty for patients and their families.
While rare genetic disorders affect fewer than one in 2,000 individuals, more than 7,000 such conditions exist, impacting approximately 400 million people globally. Approximately 80 percent of these cases are linked to genetic mutations, yet many patients endure years of grueling diagnostic odysseys, often consulting seven or eight specialists before receiving an answer.
Researchers at Radboudumc in Nijmegen and Maastricht UMC+ conducted trials with 1,000 patients, demonstrating that new long-read whole-genome sequencing improves diagnostic success by three percent over conventional methods (19.2% compared to 16.5%). This single analysis can replace as many as 15 separate tests that are typically performed in sequence, significantly conserving both time and medical resources.
Standard sequencing techniques break DNA into segments of about 300 "letters," requiring scientists to reconstruct the genome like a massive puzzle without a reference image. In contrast, this new technology reads sequences of up to 20,000 units at once, providing an immediate and clear view of how major components of the genetic puzzle fit together.
Beyond identifying gene sequences, the test also detects epigenetic modifications—chemical markers that effectively act as "on-off" switches for gene activity. These modifications previously required complex, standalone tests; now, they are integrated into a single procedure, essentially providing two critical insights in one go.
During a dedicated "undiagnosed cases hackathon" in Nijmegen, nearly 150 experts from every university medical center in the Netherlands convened to tackle the toughest cases. Their mission was to find answers for 33 families who had already exhausted all conventional testing options. By combining detailed DNA analysis with collective expertise, the team successfully identified 15 previously hidden diagnoses.
The findings, published in the New England Journal of Medicine, led scientists to recommend long-read sequencing as the first-choice standard for suspected rare genetic diseases. Professor of Translational Genomics Lisenka Vissers noted that this approach eliminates years of waiting, prevents unnecessary testing, and allows families to plan for the future with a clear understanding of what to expect.
As genetic databases expand and the links between mutations and diseases become clearer, the precision of these tests will continue to improve. Researchers estimate that reinterpreting existing data in light of new discoveries could potentially increase diagnostic rates by up to 15 percent, offering hope to hundreds more families.
These advancements are paving the way for a more accurate and deeply compassionate approach to diagnosing rare diseases.
